Dear Colleagues,

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Antibiotics* (ISSN 2079-6382). *Antibiotics* is an international, peer-reviewed, open access journal (free for readers), which publishes on all aspects of antibiotics.

Manuscripts prepared in Microsoft Word or LaTeX can be submitted to the Editorial Office online at www.mdpi.com. Detailed instructions for authors are also available online: www.mdpi.com/journal/antibiotics/instructions/

*Antibiotics* is published in open access format—research articles, reviews and other content are released on the Internet immediately after acceptance. The scientific community and the public have unlimited and free access to the content as soon as it is published.

As an open access journal, *Antibiotics* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. More information is available at www.mdpi.com/about/apc/

We would be pleased to welcome you as one of our authors.

Prof. Dr. Christopher C. Butler
Editor-in-Chief

*Antibiotics* Editorial Office
E-Mail: antibiotics@mdpi.com
Tel. +41 61 683 7734
www.mdpi.com/journal/antibiotics/

---

**Call for Papers**

**Aims & Scope**

*Antibiotics* is a multi-disciplinary journal encompassing the general fields of biochemistry, chemistry, genetics, microbiology, pharmacology, epidemiology, health economics, and social sciences aspects of antibiotics and antimicrobial research and practice. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. Therefore, there is no restriction on the length of papers.

There are, in addition, unique features of this journal: manuscripts regarding original research and ideas will be particularly welcomed. *Antibiotics* also accepts reviews, clinical studies and case reports, communications, and short notes; computed data or files regarding the full details of experimental procedures can be deposited as supplementary material.

The scope of *Antibiotics* includes:

- advances in research on new and current antibiotics and related bioactive medicinal agents
- antibiotic administration, drug-drug interactions and pharmacodynamics
- biochemical and genetics studies on microorganisms for improved antibiotics
- uses of antibiotics, including on animals and in agriculture
- clinical trials
- new methods for assaying and evaluating antibiotics
- production and characterization of antibiotics
- classes of antibiotics
- antibiotic resistance and misuse
- natural antibiotics
- epidemiology of antimicrobial use
- antimicrobial stewardship
- qualitative and quantitative research exploring the determinants of antimicrobial use and resistance
- prescribing sciences

*Antibiotics* is indexed by CAS - Chemical Abstracts, EMBASE, CAB Abstracts and a variety of other indexing and abstracting databases. A full list is available at: www.mdpi.com/journal/antibiotics/indexing/

---

**Open Access. What does it really mean?**

Open access is mainly a response to what is known as the serials crisis: yearly increasing journal subscription prices, which make subscription-based journals increasingly difficult to afford.

Many university libraries around the world have had to cancel existing subscriptions, or are unable to keep up with subscribing to new journals, because the cost of publication has risen disproportionately to their budgets.

With open access publishing, the cost of peer-review and production of an article is borne by the institute of the author by payment of a one-time flat fee. Conversely, readers and their institutes are no longer charged for accessing the journals they need.

For researchers, open access brings the convenience of immediate access to the literature that they need — no matter for which university or company they work, or whether they just want to read a paper in their spare time at home.

For authors, open access means a much wider circle of readers due to the easy access to their research papers. The interested general public is also able to access research works, giving higher transparency to the outcome of taxpayer money spent on research.

---

**Publication Ethics Statement**

*Antibiotics* is a member of the Committee on Publication Ethics (COPE). *Antibiotics* takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication.

![COPE](https://www.copublication.org/assets/logo-80.png)